MedTrace Logo

Longitudinal Study of Oscillatory Positive Expiratory Pressure (oPEP) in Stable COPD

NCT02282189 · Status: COMPLETED · Phase: NA · Type: INTERVENTIONAL · Enrollment: 17

Last updated 2018-06-27

No results posted yet for this study

Summary

The purpose of this study is to evaluate the safety and efficacy of four times daily oscillatory Positive Expiratory Pressure (oPEP) (Aerobika ®) use over 4 weeks in individuals with stable chronic obstructive pulmonary disease (COPD). The investigators hypothesize that daily oPEP use will significantly improve St. George's Respiratory Questionnaire (SGRQ) score, six-minute walk distance (6MWD) and forced expiratory volume in one second (FEV1) after four weeks of four times daily administration.

Conditions

Interventions

DEVICE

Oscillating Positive Expiratory Pressure (Aerobika ®)

The oPEP system combines positive expiratory pressure therapy and airway vibrations to help mobilize pulmonary secretions. oPEP therapy enforces a resistance to exhalation at the mouth, while the airway vibration technology transmits movements upstream during exhalation so that airway walls may become free from mucous. Subjects will take home the device and use four times daily during the active part of the study.

Sponsors & Collaborators

  • London Health Sciences Centre

    collaborator OTHER

  • Western University, Canada

    lead OTHER

Principal Investigators

  • Grace E Parraga, PhD · Robarts Research Institute, The University of Western Ontario

  • David G McCormack, MD · London Health Sciences Centre

Study Design

Purpose
TREATMENT
Masking
NONE
Model
CROSSOVER

Eligibility

Min Age
50 Years
Max Age
85 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2012-07-31
Primary Completion
2013-01-31
Completion
2013-01-31

Countries

  • Canada

Study Locations

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT02282189 on ClinicalTrials.gov